Our Team

Dr. Chen was raised in China and received his PhD in Physical Chemistry from MIT in Cambridge, Massachusetts. His PhD work was recognized by the American Chemical Society as the best thesis of the year with the distinguished Nobel Laureate Signature Award in 1990. He started his career as an assistant professor in the College of Chemistry at the University of California Berkeley, with a joint appointment as a senior faculty scientist at the Lawrence Berkeley Laboratory.

While at Berkeley, Yong built the first femtochemistry lab in the University of California System. He was an Alfred P. Sloan Research Fellow and won both the Henry Dreyfus Young Investigator award and the NSF Presidential Young Investigator award. He later joined the renowned Bell Laboratories. Dr. Chen has more than 20 issued and pending US and international patents. Prior to co-founding Genotix, Dr. Chen founded Xitogen Technologies, which was acquired by Beckman Coulter Life Sciences. Post-acquisition, he became the Chief Technology Officer. He is the inventor and architect of the CytoFLEX product portfolio, which has been a major contributor to the growth of Beckman Coulter Life Sciences.

Glenn Takayama is an entrepreneur and engineer with a strong track record of building fast-growing, successful biotech companies.

Prior to joining Genotix, he was the Founder and President of PathCom Systems (now part of Nichirei Biosciences) and Lab Vision Corporation (now part of Thermo). He also founded Spring Biosciences (now part of Roche). Previously, he worked at BioGenex, Capetronics, Memorex, Lockheed, and Western Electric.

He lends his business expertise on the boards of five companies and serves as an advisor to the Haas Business School at the University of California, Berkeley. He is an inventor on seven patents.

Takayama holds an M.B.A. from the University of California, Berkeley, and a B.S. in Engineering from the University of California, Berkeley.

George Brittain is a life scientist with many years of expertise related to reagent, assay, and instrument R&D. Since co-founding Genotix in 2019, he has worked on optimizing particle chemistries and conjugations, formulating reagents and buffers, developing assays and protocols, testing prototype instruments and software, and preparing patent applications and peer-reviewed publications.

Prior to joining Genotix, George worked from 2012-2019 in the Advanced Life Science Research group at Beckman Coulter Life Sciences, primarily focused on innovating cell-signaling assays and reagents for complex sample preparation, optimizing highly multiparametric cancer panels, enabling small particle and extracellular vesicle detection and analyses, and optimizing the engineering of flow cytometers and related instruments. He also collaborated with customers and key opinion leaders, disseminated scientific innovations, evaluated companies and technologies for potential licensing and acquisitions, consulted across departments as a subject matter expert for multiple fields, and many other functions.

George received his PhD in Neuroscience from the University of Miami Miller School of Medicine in 2009, specializing in molecular neuroimmunology, followed by a postdoctoral fellowship in molecular cancer immunology at the University of Texas MD Anderson Cancer Center in Houston, TX.

Pan Mao brings to Genotix over 10 years of experience in technology innovation and management in life science industries. Previously, he co-founded Newomics and was essential in building the company from the ground up through successful commercialization. He led the development and launch of several products including the flagship M3 emitter as the first multi-nozzle emitter for mass spectrometry.

Pan obtained his B.S. degree from the University of Science and Technology of China (USTC) and PhD in Mechanical Engineering from the Massachusetts Institute of Technology (MIT). He completed his postdoctoral training at Lawrence Berkeley National Laboratory.